A study being presented at the 2024 American Society of Hematology Annual Meeting & Exposition found that a significant proportion of multiple myeloma (MM) cases can be attributed to modifiable risk factors, such as elevated body mass index (BMI) and diabetes mellitus (DM), which disproportionately affect Black populations compared to White. For this study, Dr. Urvi Shaha of Weill Cornell Medical College, and colleagues calculated the excess MM risk due to these factors in Black and White patients. The team used data on MM cases from the US Cancer Statistics database from 2016 to 2021. The researchers also obtained data on patients who were overweight or obese from the Behavioral Risk ...
Disparities in Multiple Myeloma
Advertisement
Patients who were Black or female were more likely to refuse treatment for multiple myeloma.
The study looked at disparities in outcomes of infusion with ide-cel or cilta-cel in patients with relapsed or refractory MM.
Significant delays in diagnosing multiple myeloma exist.
Talquetamab is a promising treatment for relapsed multiple myeloma, however, it presents unique side effects.
In MM patients, prescription delays were linked to Black race, older age, inpatient diagnosis, and severe renal impairment.
There is a disproportionately high MM incidence and mortality among non-Hispanic Black Americans.
Dr. Ailawadhi explores ways that researchers are designing trials to address racial disparities in enrollment.
Dr. Ailawadhi explained how oncologists should consider racial differences when approaching clinical care.
Advertisement
Expert Interviews
Urban Health Today reports on clinical news and policy updates that directly impact urban health care providers and their patients.
Get research and expert insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.